Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer
Abstract
Immunotherapy has failed to achieve durable remissions in advanced prostate cancer patients. More potent T-cell–redirecting strategies may be needed to overcome the immunologically exclusive and suppressive tumor microenvironment. Clinical trials are underway, seeking to define the optimal target for T-cell redirection, such as PSMA, PSCA, or STEAP-1, as well as the optimal strategy, with CAR or bispecific antibodies. As results continue to emerge from these trials, understanding differential toxicity and efficacy of these therapies based on their targets and functional modifications will be key to advancing these promising therapies toward clinical practice. This review provides a unique depth and breadth of perspective regarding the diverse immunotherapy strategies currently under clinical investigation for men with advanced prostate cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 21, 2021
- Source ID
- 10.1158/1078-0432.ccr-21-1483
Entities
People
- Carl H. June
- Joseph A. Fraietta
- Naomi B. Haas
- Peter D. Zang
- Saul J Priceman
- Stephen J. Forman
- Tanya B. Dorff
- Vivek Narayan
Organizations
- City of Hope National Medical Center
- National Cancer Institute
- Prostate Cancer Foundation
- United States Department of Defense
- University of Pennsylvania